BriaCell Therapeutics (TSX.V: BCT) (OTCQB: BCTXF), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, today announced that it has achieved proof of concept in the Phase IIa study of its lead clinical candidate, Bria-IMT™, in advanced breast cancer. The data demonstrates promising anti-tumor activity of Bria-IMT™ in heavily pre-treated advanced breast cancer patients. The company is focusing on the combination study of the candidate with pembrolizumab (Keytruda®; manufactured by Merck & Co., Inc.) or ipilimumab (Yervoy®; manufactured by Bristol-Myers Squibb Company) to boost the anti-tumor activity of Bria-IMT™. Given the conclusive findings of the first 20 patients in the Phase IIa Bria-IMT™ monotherapy study, enrollment for the study is now closed. The company has initiated a combination study of Bria-IMT™ for which enrollment is now open. “Bria-IMT™ appears to be most effective in patients who match with Bria-IMT™ at 2 HLA loci (types) further supporting BriaCell’s HLA Matching Hypothesis, and the development of Bria-OTS™ to cover 90% of the patient population. We are delighted with these positive clinical findings that confirm our HLA Matching Hypothesis in the Phase I/IIa trial in advanced breast cancer showing significant tumor shrinkage without serious side effects,” BriaCell Therapeutics president and CEO Dr. Bill Williams stated in the news release. “We believe that combination studies with immune checkpoint inhibitors should create even more potent anti-cancer immune responses, leading to our strategy of combination studies of Bria-IMT™ with Keytruda® or Yervoy®.”
BriaCell is hosting a webcast at 4:15pm ET to discuss the results. The company’s president and CEO Dr. Bill Williams will present Bria-IMT™’s proof of concept clinical data during the webcast. To join the webcast, call the toll-free line in North America at 1-855-327-6837; the Toronto line at 1-416-915-3239; the Montreal line at 1-514-375-0364; or the Vancouver line at 1-778-327-3988. To listen to a replay of the webcast, call the toll-free line in North America at 1-844-512-2921.
To view the slide presentation to follow along with the webcast, visit http://nnw.fm/5V9Aj
To view the full press release, visit http://nnw.fm/G3FrL
About BriaCell
BriaCell is an immuno-oncology focused biotechnology company developing targeted and safe approaches for the management of cancer. BriaCell is currently conducting a Phase I/IIa clinical trial of Bria-IMT™, its lead candidate, in a combination study with pembrolizumab [Keytruda®; manufactured by Merck & Co., Inc.] or ipilimumab [Yervoy®; manufactured by Bristol-Myers Squibb Company]. The combination study is listed in ClinicalTrials.gov as NCT03328026. BriaCell is developing Bria-OTS™, an off-the-shelf personalized immunotherapy, for advanced breast cancer. Bria-OTS™ immunotherapy treatments are personalized to match the patient without the need for personalized manufacturing. Bria-OTS™, which is expected to cover over 90% of the patient population, is designed to produce a potent and selective immune response against the cancer of each patient while eliminating the time, expense, and complex manufacturing logistics associated with other personalized immunotherapies. For more information, visit the company’s website at www.BriaCell.com
More from NetworkNewsBreaks
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive instant SMS alerts, text STOCKS to 77948
For more information please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com